Technical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea Biosciences

Monday, March 26, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 26, 2018 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment

community.  Today we are offering reports on EYEG, FATE, FGEN, and GNCA which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallSEquities.com monitors Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG), Fate
Therapeutics Inc. (NASDAQ: FATE), FibroGen Inc. (NASDAQ: FGEN), and Genocea Biosciences Inc. (NASDAQ: GNCA). These stocks belong to the Biotechnology industry, which is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies that reside in it. Markets served include Medical, Agricultural, Environmental, and Industrial. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Eyegate Pharmaceuticals

Waltham, Massachusetts headquartered Eyegate Pharmaceuticals Inc.'s stock finished last Friday's session 4.58% lower at $0.46. A total volume of 270,704 shares was traded. The Company's shares are trading below their 50-day moving average by 42.53%. Additionally, shares of Eyegate Pharma, which focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye, have a Relative Strength Index (RSI) of 24.51.  

On March 08th, 2018, Eyegate Pharma announced that it has submitted an amended Investigational Device Exemption (IDE) application to the US Food and Drug Administration (FDA) for a pilot study of the Company's lead product, EyeGate Ocular Bandage Gel, a cross-linked thiolated carboxymethyl hyaluronic acid platform. The amendment summarizes the Company's responses to the FDA's questions and comments in response to the original IDE submission. Get the full research report on EYEG for free by clicking below at: www.wallstequities.com/registration/?symbol=EYEG

Fate Therapeutics

On Friday, shares in San Diego, California headquartered Fate Therapeutics Inc. ended the session 0.36% lower at $10.92. The stock recorded a trading volume of 686,106 shares. The Company's shares have gained 3.21% in the last month, 142.13% in the previous three months, and 135.34% over the past year. The stock is trading 10.85% above its 50-day moving average and 101.38% above its 200-day moving average. Moreover, shares of Fate Therapeutics, which develops programmed cellular immunotherapies for cancer and immune disorders worldwide, have an RSI of 46.50.  

On March 05th, 2018, Fate Therapeutics reported its financial results for Q4 ended December 31st, 2017. Revenue for Q4 2017 was $1.0 million; total operating expenses were $13.3 million; R&D expenses were $9.9 million; and G&A expenses were $3.4 million. Cash, cash equivalents, and short-term investments were $100.9 million as of December 31st, 2017.

On March 06th, 2018, research firm H.C. Wainwright downgraded the Company's stock rating from 'Buy' to 'Neutral', with a target price of $12 per share. Access the free research report on FATE now by signing up at: www.wallstequities.com/registration/?symbol=FATE

FibroGen

San Francisco, California headquartered FibroGen Inc.'s shares dropped 4.50%, closing the session at $46.70 with a total trading volume of 499,853 shares. The stock has gained 4.83% over the previous three months and 86.43% over the past year. The stock is trading 0.04% below their 200-day moving average. Additionally, shares of FibroGen, which discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs, have an RSI of 31.53.  

On March 01st, 2018, FibroGen announced that the US FDA has granted Fast Track designation for the Company's anti-CTGF antibody, pamrevlumab, for the treatment of patients with locally advanced unresectable pancreatic cancer. This follows review of the Phase-2 clinical trial evaluating pamrevlumab in combination with gemcitabine and nab-paclitaxel and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease. Are you already registered with Wall St. Equities? Do so now for free, and get the report on FGEN at: www.wallstequities.com/registration/?symbol=FGEN

Genocea Biosciences

Last Friday at the close of trading, shares in Cambridge, Massachusetts headquartered Genocea Biosciences Inc. recorded a trading volume of 411,414 shares. The stock ended the session 4.27% lower at $1.12. The Company's shares have advanced 9.80% in the past month and 5.66% over the previous three months. The stock is trading above its 50-day moving average by 9.62%. Furthermore, shares of Genocea Biosciences, which discovers and develops novel cancer vaccines, have an RSI of 53.25.  

On March 12th, 2018, Genocea Biosciences (GNCA) announced the appointment of Narinder Singh as senior vice president of pharmaceutical sciences and manufacturing. Mr. Singh will be responsible for overseeing GNCA's manufacturing strategy including for GEN-009, the Company's personal neoantigen cancer vaccine candidate. Aspiring Member, please take a moment to register below for your free research report on GNCA at: www.wallstequities.com/registration/?symbol=GNCA

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

 

Cision View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----eyegate-pharma-fate-therapeutics-fibrogen-and-genocea-biosciences-300619235.html

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store